Wall Street equity research analysts tracking Evolus (NASDAQ: EOLS) maintain a strongly favorable consensus, generally carrying Buy to Strong Buy ratings. Institutional enthusiasm is driven by robust double-digit revenue growth from its Jeuveau franchise and a clear path toward sustainable operational profitability in the aesthetics sector.